Back

Beneficial metabolic effects of 2-week ketone ester in patients with type 2 diabetes and heart failure with preserved ejection fraction.

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Heart failure in the era of precision medicine: insights into pathophysiology and emerging treatments Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Nigopan Gopalasingam

Aarhus University Hospital, Aarhus (Denmark)

5 More presentations in this session

Presentation thumbnail
Body mass related epigenetic reprogramming and downstream analysis in heart failure phenotypes
Miss E. Yapici (Mainz, DE)
Abstract Slides Video
Presentation thumbnail
Long COVID: insights from echocardiography, cardiac magnetic resonance, and endomyocardial Biopsies in previous healthy individuals with persistent chest pain
Doctor O. Gomez Monterrosas (Puebla, MX)
Abstract Slides Video
Presentation thumbnail
A characterisation of mitochondrial structure, oxidative phosphorylation capacity, and amyloid burden in patients with wild-type transthyretin cardiomyopathy
Doctor B. Ladefoged (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
The effect of spironolactone on infections in heart failure with preserved ejection fraction
Doctor B. Szabo-Soderberg (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Systemic microvascular dysfunction in heart failure with preserved ejection fraction: the PROSE-HFpEF case-control study
Doctor J. Weerts (Maastricht, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure in the era of precision medicine: insights into pathophysiology and emerging treatments
Video

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Metabolic effects of 14-day oral ketone ester treatment in patients with heart failure with reduced ejection fraction
thumbnail
Congress Presentation
Effect of exogenous ketone supplementation on cardiac energetics, function, and perfusion in type 2 diabetes, heart failure, and healthy participants- A single center, open labelled clinical study.
thumbnail
Congress Presentation
Ketones-based signalling in heart failure with preserved ejection fraction (HFpEF)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources